Navigation Links
SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007
Date:11/13/2007

increased costs related to the development of our MET inhibitors. The decrease of $4.6 million for the nine month period was primarily attributable to a decrease of costs incurred for Troxatyl(TM) clinical trial activities, a reduction in subcontractor expenditures associated with our federal research grant, and lower depreciation expense.

General and administrative expenses for the three months ended September 30, 2007 and 2006 were $2.1 million and $1.9 million, respectively. General and administrative expenses for the nine months ended September 30, 2007 and 2006 were $6.4 million and $7.4 million, respectively. The increase of $0.2 million for the three month period was primarily attributable to increased professional services. The decrease of $1.0 million for the nine month period was primarily attributable to a decrease in non-cash stock-based compensation expense, together with a decrease in recruiting, salaries and professional services.

SGX reported a net loss attributable to common stockholders for the three months ended September 30, 2007 of $4.8 million, or $0.31 per share. This compares with a net loss attributable to common stockholders for the three months ended September 30, 2006 of $3.4 million, or $0.23 per share. For the nine months ended September 30, 2007, the net loss attributable to common stockholders was $9.9 million, or $0.65 per share. This compares with a net loss attributable to common stockholders for the nine months ended September 30, 2006 of $23.2 million, or $1.74 per share.

About SGX Pharmaceuticals

SGX Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics. The SGX oncology pipeline includes drug candidates from its FAST (TM) drug discovery platform, such as next generation BCR-ABL inhibitors being developed by SGX and in partnership with Novartis and MET tyrosine kinase inhibitors, including SGX523, and potent JAK2 inhibitors
'/>"/>

SOURCE SGX Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 Keystone Symposia will convene the first ... its 2014-15 Global Health Series on "The Modes ... Hotel immediately following the conclusion of the Grand ... is part of the Keystone Symposia Global Health Series, ... has also funded travel awards for 36 investigators from ...
(Date:9/30/2014)... York, NY (PRWEB) September 30, 2014 ... falling demand have hampered growth in the Bread ... diets have caused consumers to moderate their consumption ... consumer preferences for premium varieties shrunk the market ... products. Successful operators proactively responded by introducing more ...
(Date:9/30/2014)... Irvine, Calif., Sept. 30, 2014 Research by UC ... system functions, shedding light on a vital process that ... , In the online version of Nature Immunology ... Zhou and other Institute for Immunology colleagues describe a ... and released into the bloodstream. , A T cell ...
(Date:9/30/2014)... NV (PRWEB) September 30, 2014 ... Blue Star Nutraceuticals designed to help maximize lean, strong ... optimizes the body’s absorption of glucose has caught the ... , “The main purpose behind Glycodrive is to help ... lean muscle,” reports Michaels. “Carbs are essential in the ...
(Date:9/30/2014)... Elevate , the latest product from Blue Start ... of the gym by providing natural ingredients that boost brain ... Michaels, prompting an investigative review. , “When it comes ... simply just don’t have the ability to perform the way ... the motivation to finish a project, or even feeling like ...
Breaking Medicine News(10 mins):Health News:Keystone Symposia launches 2014-2015 meeting series with Global Health Vaccines Conference 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:UCI study uncovers important process for immune system development 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2
... the University of Pennsylvania School of Medicine have discovered ... of an important heart muscle protein called actin. Whats ... the pumping unit of the heart. The findings appear ... was known about Lmod when we began this study, ...
... JEFFERSONVILLE, Ind., April 10 Meijer customers ... carts. PetFirst,Healthcare LLC recently launched a partnership to ... throughout the Midwest., PetFirst insurance covers routine ... is now offered through cards displayed on freestanding ...
... band campaign, looks forward to taking ... April 10 Safe Kids Worldwide,the first-ever ... has named Mitchell R. Stoller as its ... announced today., (PHOTO: http://www.newscom.com/cgi-bin/prnh/20080410/DC19130-a ...
... and Exclusive Auction to be Held on Saturday, April 12th at the ... Helen Mills ... Kristin,Chenoweth, announced she will be performing a benefit concert on Saturday,April 12th ... The concert, titled, "Kristin Chenoweth, This One,s Personal: A,Concert to Stop ACD," ...
... ANA, Calif., April 10 Integrated,Healthcare Holdings, Inc. ... named Edward S. Gyimah as its Chief Compliance ... regulation of its,hospitals. Since 2006, Gyimah has worked ... instrumental in establishing and implementing the Company,s,Sarbanes-Oxley compliance ...
... of infants distinguish differences in sounds and it may ... start to speak, sparing them the difficulties that come ... Professor of Neuroscience April Benasich and her Infancy Studies ... and exciting clues about how infant brains begin to ...
Cached Medicine News:Health News:Penn researchers discover 'modus operandi' of heart muscle protein 2Health News:Meijer Supercenters to Offer PetFirst Insurance in Pet Aisles 2Health News:Safe Kids Worldwide Names Stoller New President, CEO 2Health News:Safe Kids Worldwide Names Stoller New President, CEO 3Health News:Kristin Chenoweth to Perform Benefit Concert for 3 Angels Memorial Fund titled, 'Kristin Chenoweth, This One's Personal: A Concert to Stop ACD' 2Health News:Kristin Chenoweth to Perform Benefit Concert for 3 Angels Memorial Fund titled, 'Kristin Chenoweth, This One's Personal: A Concert to Stop ACD' 3Health News:IHHI Announces Chief Compliance Officer Appointment 2Health News:Impairments in language development can be detected in infants as young as 3 months 2Health News:Impairments in language development can be detected in infants as young as 3 months 3
(Date:9/30/2014)... 30, 2014 According ... Market by Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), ... Reagents], Application (Immunology, Oncology) & by End ... by MarketsandMarkets, provides a detailed overview of ... market trends, and strategies impacting the global ...
(Date:9/30/2014)... ANGELES , Sept. 30, 2014   Easy ... shopping destination , today announced that it now offers ... . AirSense CPAPs are the first sleep apnea therapy ... it simple and easy to track and share real-time ... overall effectiveness of their CPAP therapy.  In addition, the ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 ... stage. Growing ageing population and rise in the incidence ... of chronic wounds and in affordability of better quality ... Chinese wound care market. Universal coverage of public health ... products would further stimulate demand. Based on the findings ...
Breaking Medicine Technology:Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4China Wound Care Market 2China Wound Care Market 3
... SRI International and the Stanford University School of ... Technology Research Advanced Laboratory), in conjunction with the Institute for Pediatric ... Food and Drug Administration (FDA) to support its work to commercialize ... , , ...
... MUNDELEIN, Ill. , July 22 Sysmex America, ... and information systems, today announced a partnership agreement with Medica ... to laboratories in North America , Mexico ... and Columbia . Sysmex America will be responsible for ...
Cached Medicine Technology:SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 2SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 3SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 4SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 5SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 6SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 7Sysmex America and Medica Corporation Announce Distribution Partnership 2Sysmex America and Medica Corporation Announce Distribution Partnership 3
... stage is a refrigerated design for use as ... use with the 8000 sledge microtome, however, it ... refrigerated stage gives a large working area of ... to provide good adhesion between the specimen and ...
... For some sectioning work, it is necessary to ... State Freezer can be fitted to most microtomes ... -25C or lower, depending on conditions. The equipment ... unit. The cooling stage is best suited for ...
... is necessary to cool a specimen below room ... to most microtomes and will permit specimen cooling ... conditions. The equipment consists of a cooling stage ... best suited for operation with a base sledge ...
... MNL 4404 & 4405 series Freezing Stages fit ... have no moving parts and need only the ... for operation. Freezing starts immediately and ... adjustable so that optimum cutting temperatures can be ...
Medicine Products: